Diagnostic Automation/Cortez Diagnostics, Inc.

IMMUNO DIAGNOSTICS

AccuDiag™ β2-Glycoprotein 1 IgG ELISA Kit

REF 1495-55

IVD | See External Label | 2°C–8°C | Σ 96 Tests

β2-Glycoprotein 1 IgG ELISA	
Principle	Indirect ELISA
Detection	Semiquantitative and quantitative
Sample	5 µL serum/plasma
Incubation Time	80 minutes
Detection Limit	1.8 RU/ml
Specificity	100%
Shelf Life	12 Months from the manufacturing date

PRODUCT FEATURES

- Very easy to use with little training
- Highly specific and consistent assay
- Provides accurate results quickly
- Reading of results both visually and as absorbance data

INTENDED USE

The Diagnostic Automation Inc. AccuDiag™ Anti-β2-Glycoprotein 1 (IgG) ELISA Kit is used to detect Anti-phospholipid syndrome.

ASSAY PRINCIPLE

The ELISA test kit provides a semi-quantitative or quantitative in vitro assay for human IgG class antibodies against β2-glycoprotein 1 (β2-GP1) in serum or plasma. The test kit contains microtiter strips each with 8 break-off reagent wells coated with β2-GP1. In the first reaction step, diluted patient samples are incubated with the wells. In the case of positive samples, specific IgG antibodies (also IgA and IgM) will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labelled anti-human IgG (enzyme conjugate) catalyzing a color reaction.

MATERIALS AND COMPONENTS

Materials provided with the test kit

Component	Color	Format	Symbol
1.Microplate wells, Coated with antigens: 12 microplate strips each containing 8 individual break-off wells in a frame, ready for use	---	12 x 8	STRIPS
2.Calibrator 1 200 RU/ml (IgG, human), ready for use	Dark red	1 x 2.0 ml	CAL 1
3.Calibrator 2 20 RU/ml (IgG, human), ready for use	Red	1 x 2.0 ml	CAL 2
4.Calibrator 3 2 RU/ml (IgG, human), ready for use	Light red	1 x 2.0 ml	CAL 3
5.Positive control (IgG, human), ready for use	Blue	1 x 2.0 ml	POS CONTROL
6.Negative control (IgG, human), ready for use	Green	1 x 2.0 ml	NEG CONTROL
7.Enzyme conjugate Peroxidase-labelled anti-human IgG (rabbit)	Green	1 x 12 ml	CONJUGATE
8.Sample buffer ready for use	Light blue	1 x 100 ml	SAMPLE BUFFER
9.Wash buffer 10x concentrate	Colorless	1 x 100 ml	WASH BUFFER 10x
10.Chromogen/substrate solution TMB/H_2O_2, ready for use	Colorless	1 x 12 ml	SUBSTRATE
11.Stop solution 0.5M sulfuric acid, ready for use	Colorless	1 x 12 ml	STOP SOLUTION
12.Test instruction	---	1 booklet	
13.Quality control certificate	---	1 protocol	

STORAGE CONDITIONS

The test kit has to be stored at a temperature between +2°C to +8°C. The calibrators and positive control must be stored in aliquots at -20°C. Unopened, all test kit components are stable until the indicated expiry date.

WASTE DISPOSAL

Patient samples, calibrators, controls and incubated microplate strips should be handled as infectious waste. All reagents must be disposed of in accordance with local disposal regulations.

REAGENT PREPARATION

Note: All reagents must be brought to room temperature (+18°C to +25°C) approx. 30 minutes before use. After first use, the reagents are stable until the indicated expiry date if stored at +2°C to +8°C and protected from contamination, unless stated otherwise below.

– **Coated wells:** Ready for use. Tear open the resealable protective wrapping of the microplate at the recesses above the grip seam. Do not open until the microplate has reached room temperature to prevent the individual strips from moistening. Immediately replace the remaining wells of a partly used microplate in the protective wrapping and tightly seal with the

integrated grip seam (Do not remove the desiccant bag). Once the protective wrapping has been opened for the first time, the wells coated with antigens can be stored in a dry place and at a temperature between +2°C and +8°C for 4 months.

- **Calibrators and controls:** Ready for use. The reagents must be mixed thoroughly before use.
- **Enzyme conjugate**: Ready for use. The enzyme conjugate must be mixed thoroughly before use.
- **Sample buffer:** Ready for use.
- **Wash buffer**: The wash buffer is a 10x concentrate. If crystallization occurs in the concentrated buffer, warm it to 37°C and mix well before diluting. The quantity required should be removed from the bottle using a clean pipette and diluted with deionized or distilled water (1 part reagent plus 9 parts distilled water). For example: For 1 microplate strip, 5 ml concentrate plus 45 ml water. The working strength wash buffer is stable for 4 weeks when stored at +2°C to +8°C and handled properly.
- **Chromogen/substrate solution:** Ready for use. Close the bottle immediately after use, as the contents are sensitive to light. The chromogen/substrate solution must be clear on use. Do not use the solution if it is blue colored.
- **Stop solution:** Ready for use.

Warning: Calibrators and controls used have been tested negative for HBsAg, anti-HCV, anti-HIV-1 and anti-HIV-2 using enzyme immunoassays and indirect immunofluorescence methods. Nonetheless, all materials should be treated as being a potential infection hazard and should be handled with care. Some of the reagents contain the toxic agent sodium azide. Avoid skin contact.

SPECIMEN COLLECTION & PREPARATION

Sample material: Human serum or EDTA, heparin or citrate plasma.

Stability: **Patient samples** to be investigated can generally be stored at +2°C to +8°C for up to 14 days. Diluted samples should be incubated within one working day.

Sample dilution: **Patient samples** are diluted **1:201** in sample buffer. For example: dilute 5 µl serum in 1.0 ml sample buffer and mix well by vortexing (sample pipettes are not suitable for mixing).

NOTE: Calibrators and controls are prediluted and ready for use, do not dilute them.

ASSAY PROCEDURE

INCUBATION

For **semiquantitative analysis** incubate **calibrator 2** along with the positive and negative controls and patient samples. For **quantitative analysis** incubate **calibrators 1, 2 and 3** along with the positive and negative controls and patient samples.

(Partly) manual test performance

Sample incubation: (1st step)
Transfer 100 µl of the calibrators, positive and negative controls or diluted patient samples into the individual microplate wells according to the pipetting protocol. Incubate for **30 minutes** at room temperature (+18°C to +25°C).

Washing:
Manual: Empty the wells and subsequently wash 3 times using 300 µl of working strength wash buffer for each wash.
Automatic: Wash reagent wells 3 times with 450 µl working strength wash buffer (program setting: e.g. TECAN Columbus Washer "Overflow Mode").

Leave the wash buffer in each well for 30 to 60 seconds per washing cycle, then empty the wells. After washing (manual and automated tests), thoroughly dispose of all liquid from the microplate by tapping it on absorbent paper with the openings facing downwards to remove all residual wash buffer.

Note: Residual liquid (> 10 µl) remaining in the reagent wells after washing can interfere with the substrate and lead to false low extinction values. Insufficient washing (e.g., less than 3 wash cycles, too small wash buffer volumes, or too short reaction times) can lead to false high extinction values.
Free positions on the microplate strip should be filled with blank wells of the same plate format as that of the parameter to be investigated.

Conjugate incubation: (2nd step)
Pipette 100 µl of enzyme conjugate (peroxidase-labelled anti-human IgG) into each of the microplate wells. Incubate for **30 minutes** at room temperature (+18°C to +25°C).

Washing:
Empty the wells. Wash as described above.

Substrate incubation: (3rd step)
Pipette 100 µl of chromogen/substrate solution into each of the microplate wells. Incubate for **15 minutes** at room temperature (+18°C to +25°C) protect from direct sunlight.

Stopping:
Pipette 100 µl of stop solution into each of the microplate wells in the same order and at the same speed as the chromogen/substrate solution was introduced.

Measurement:
Photometric measurement of the colour intensity should be made at a **wavelength of 450 nm** and a reference wavelength between 620 nm and 650 nm **within 30 minutes of adding the stop solution**. Prior to measuring, slightly shake the micro-plate to ensure a homogeneous distribution of the solution.

Test performance using fully automated analysis devices

Sample dilution and test performance are carried out fully automatically using the analysis device. The incubation conditions programmed in the respective software authorized by DAI may deviate slightly from the specifications given in the ELISA test instruction. However, these conditions were validated in respect of the combination of the DAI Analyzer I, Analyzer I-2P or the DSX from Dynex and this DAI ELISA. Validation documents are available on inquiry.
Automated test performance using other fully automated, open system analysis devices is possible, however, the combination should be validated by the user.

PIPETTING PROTOCOL

	1	2	3	4	5	6	7	8	9	10	11	12
A	C 2	P 6	P 14	P 22			C 1	P 4	P 12	P 20		
B	pos.	P 7	P 15	P 23			C 2	P 5	P 13	P 21		
C	neg.	P 8	P 16	P 24			C 3	P 6	P 14	P 22		
D	P 1	P 9	P 17				pos.	P 7	P 15	P 23		
E	P 2	P 10	P 18				neg.	P 8	P 16	P 24		
F	P 3	P 11	P 19				P 1	P 9	P 17			
G	P 4	P 12	P 20				P 2	P 10	P 18			
H	P 5	P 13	P 21				P 3	P 11	P 19			

The pipetting protocol for microtiter strips 1-4 is an example for the **semiquantitative analysis** of 24 patient samples (P 1 to P 24).
The pipetting protocol for microtiter strips 7-10 is an example for the **quantitative analysis** of 24 patient samples (P 1 to P 24).

The calibrators (C 1 to C 3), the positive (pos.) and negative (neg.) controls, and the patient samples have each been incubated in one well. The reliability of the ELISA test can be improved by duplicate determinations for each sample.
The wells can be broken off individually from the strips. This makes it possible to adjust the number of test substrates used to the number of samples to be examined and minimizes reagent wastage. Both positive and negative controls serve as internal controls for the reliability of the test procedure. They should be assayed with each test run.

RESULTS

Semiquantitative: Results can be evaluated semi-quantitatively by calculating a ratio of the extinction value of the control or patient sample over the extinction value of calibrator 2. Calculate the ratio according to the following formula:

$$\frac{\text{Extinction of the control or patient sample}}{\text{Extinction of calibrator 2}} = \text{Ratio}$$

DAI recommends interpreting results as follows:

Ratio < 1.0:	**Negative**
Ratio ≥ 1.0:	**Positive**

Quantitative: The standard curve from which the concentration of antibodies in the serum samples can be taken is obtained by point-to-point plotting of the extinction values measured for the 3 calibration sera against the corresponding units (linear/linear). Use "point-to-point" plotting for calculation of the standard curve by computer. The following plot is an example of a typical calibration curve. Please do not use this curve for the determination of antibody concentrations in patient samples.



If the extinction for a patient sample lies above the value of calibrator 1 (200 RU/ml), the result should be given as ">200 RU/ml". It is recommended that the sample be re-tested at a dilution of 1:800. The result in RU/ml read from the calibration curve for this sample must then be multiplied by a factor of 4.

The upper limit of the normal range **(cut-off)** recommended by DAI is 20 relative units (RU)/ml. DAI recommends interpreting results as follows:

<20 RU/ml:	**negative**
≥20 RU/ml:	**positive**

For duplicate determinations the mean of the two values should be taken. If the two values deviate substantially from one another the sample should be retested.

For diagnosis, the clinical symptoms of the patient should always be taken into account along with the serological results.

PERFORMANCE CHARACTERISTICS

Calibration: As no international reference serum exists for the measurement of antibodies against β2-glycoprotein 1, the calibration is performed in relative units (RU)/ml.

For every group of tests performed, the extinction values of the calibrators and the relative units and/or ratio determined for the positive and negative controls must lie within the limits stated for the relevant test kit lot. A quality control certificate containing these reference values is included. If the values specified for the controls are not achieved, the test results may be inaccurate and the test should be repeated.

The binding activity of the antibodies and the activity of the enzyme used are temperature-dependent. It is therefore recommended using a thermostat in all three incubation steps. The higher the room temperature during the incubation steps, the greater will be the extinction values. Corresponding variations apply also to the incubation times. However, the calibrators are subject to the same influences, with the result that such variations will be largely compensated in the calculation of the result.

Antigen: The microplate wells were coated with highly purified β2-glycoprotein 1 isolated from human serum. The purity of the preparation was verified by SDS polyacrylamide gel electrophoresis (4% to 12% gel). The adjacent figure shows a molecular weight marker on track 1 of the electrophoresis, and the purified β2-GP1 applied to track 2. β2-GP1 has a molecular weight of 50 kDa, its function is not known. β2-GP1 is found in human plasma, both in the free state as well as associated with low-density lipoproteins.



Linearity: The linearity of the Anti-β2-Glycoprotein 1 ELISA (IgG) was determined by assaying 4 serial dilutions of different patient samples. The coefficient of determination R^2 for all sera was > 0.95. The Anti-β2-Glycoprotein 1 ELISA (IgG) is linear at least in the tested concentration range (9 RU/ml to 181 RU/ml).

Detection limit: The lower detection limit is defined as the mean value of an analyte-free sample plus three times the standard deviation and is the smallest detectable antibody titer. The lower detection limit of the Anti-β2-Glycoprotein 1 ELISA (IgG) is 1.8 RU/ml.

Cross reactivity: This ELISA showed no cross reactivity.

Interference: Haemolytic, lipaemic and icteric samples showed no influence on the result up to a concentration of 10 mg/ml for hemoglobin, 20 mg/ml for triglycerides and 0.4 mg/ml for bilirubin in this ELISA.

Reproducibility: The reproducibility of the test was investigated by determining the intra- and inter-assay coefficients of variation (CV) using 3 sera. The intra-assay CVs are based on 20 determinations and the inter-assay CVs on 4 determinations performed in 6 different test runs.

Intra-assay variation, n = 20		
Serum	**Mean value (RU/ml)**	**CV (%)**
1	60	7.3
2	128	5.9
3	192	4.9

Inter-assay variation, n = 4 x 6		
Serum	**Mean value (RU/ml)**	**CV (%)**
1	57	6.9
2	118	7.6
3	189	5.7

Prevalence and specificity: The prevalence anti-β2-GP1 antibodies (IgG) in a panel of 21 APS patients was 43%. The specificity in a control panel of patients with HIV, HBV or HCV (n = 168), healthy pregnant women (n = 200) and healthy blood donors (n = 206) was 100%.

Reference range: The levels of the anti-β2-GP1 antibodies (IgG) were analyzed with this DAI ELISA in 206 healthy blood donors. With a cut-off of 20 RU/ml, 0.5% of the blood donors were anti-β2-GP1 negative (IgG).

CLINICAL SIGNIFICANCE

Anti-β2-glycoprotein 1 (anti-β2-GP1) are autoantibodies (AAb) against β2-GP1 (apolipoprotein H), which was first described as a plasma protein in 1961 and characterized by molecular biological methods in 1984. This protein is a cofactor for antibody binding to the phospholipid cardiolipin.

Anti-phospholipid syndrome (APS), also called Hughes syndrome, is an autoimmune disease which is characterized by thrombophilia. Cumulative haematological signs are mainly venous (37%) or arterial (27 to 49%) thrombosis, haemocytopenia (30 to 38%), pregnancy complications (55 to 74%), neurological failures (66%) and cardiological (27%), pulmonary (20 to 30%) or cutaneous (40) tissue damage due to the above-mentioned circulatory disorders. Other APS-induced organ manifestations can include Addison's disease caused by thrombosis of the suprarenal vessels, intestinal necrosis caused by occlusion of the intestinal vessels, Budd-Chiari syndrome caused by hepatic venous thrombosis, and liver and spleen infarction. APS is an immunocoagulopathy and the most frequently acquired hypercoagulability. 82% of APS patients are women and 18% men. Around 10% of APS cases are familial.

APS is divided into primary APS (pAPS) and secondary APS (sAPS). These are characterized by the same haematological immune responses. In sAPS, however, they occur during the course of the disease as secondary reactions, most frequently in connection with rheumatic diseases (e.g. SLE). Around 1% of APS patients suffer from the most extreme form of APS, the so-called catastrophic form (cAPS), which is characterized by life-threatening multi-organ failure.

APS is proven when at least one clinical APS criterion (thrombosis or pregnancy complications) and one laboratory criterion (medium to high serum/plasma antibody titers measured at an interval of at least 12 weeks) are fulfilled. Antibody detection encompasses lupus anticoagulans (LA), anti-cardiolipin antibodies of class IgG and/or IgM (titer > 99th percentile, measured using ELISA) or anti-β2-glycoprotein-1 antibodies of class IgG and/or IgM (titer > 99th percentile, measured using ELISA).

Anti-β2-GP1 antibodies are a highly specific marker for pAPS and sAPS, the latter of which is frequently associated with collagenosis. According to the "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) 2006" the serological detection of β2-GP1 antibodies (strongest APS association of all detectable APS antibodies) is indicated as a serological criterion in APS diagnostics. The determination of anti-β2-GP1 antibodies is indispensable in suspected cases of APS that are negative for antibodies against cardiolipin or lupus anticoagulans. This is generally the case in 3%-14% of APS patients. Furthermore, anti-β2-GP1 antibodies are a biological marker for APS-induced pregnancy complications with a prevalence of approx. 6%. A positive β2-GP1 antibody result should always be assessed after at least 12 weeks to confirm diagnosis.

The prevalence of class IgG and/or IgM antibodies against β2-GP1 in APS patients is 30% to 80%. They can be detected in 50% of asymptomatic patients. This implies a prognosis of potential/probable thromboembolism, which could be prevented by early phrophylaxis. Retrospectively, there is a significant correlation between antibody concentration and past venous thrombosis. IgM antibodies correlate with arterial thrombosis. In APS patients with SLE, the severity of thrombosis correlates with the level of antibodies against β2-GP1.

The serological detection rate in APS diagnostics can be significantly increased to almost 100% by parallel investigation of antibodies against β2-GP1 (specificity approx. 98%, sensitivity approx. 60%) and cardiolipin (specificity >85%, sensitivity significantly >60%). In suspected cases of APS that show a negative result for IgG and IgM isotypes of anti-β2-GP1 and anti-cardiolipin, the IgA isotope should also be determined for both autoantibodies.

The use of the anti-cardiolipin antibody test as the only serological detection method is limited since cardiolipin antibodies also occur in tumors and in some infections (e.g. syphilis, borreliosis, AIDS, hepatitis or tuberculosis).

Antigen	Disease	AAb prevalence
β2-glycoprotein 1 (β2-GP1)	Primary anti-phospholipid syndrome (pAPS)	30% - 80%
	Secondary anti-phospholipid syndrome (sAPS)	31% - 57%
	APS-induced pregnancy complications	6%
	APS (anti-cardiolipin etc. negative)	3% - %14

REFERENCES

1. Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GR. **Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome.** Br J Rheumatol 35 (1996) 1239-1243.
2. Asherson RA, Cervera R. **Antiphospholipid antibodies and infections.** Ann Rheum Dis 62 (2003) 388-93.
3. Bizzaro N, Tonutti E, Villalta D, Tampoia M, Tozzoli R. **Prevalence and clinical correlation of antiphospholipid-binding protein antibodies in**

anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages. Arch Pathol Lab Med 129 (2005) 61-68.

4. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quéré I, Hachulla E, Vasconcelos C, Roch B, Fernández-Nebro A, Boffa MC, Hughes GR, Ingelmo M; Euro-Phospholipid Project Group. **Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.** Arthritis Rheum 46 (2002) 1019-1027.
5. Espinosa G, Cervera R. **Antiphospholipid syndrome.** Arthritis Res Ther 10 (2008) 230.
6. AG. Stöcker W, Schlumberger W, Krüger C. **Alle Beiträge zum Thema Autoimmundiagnostik.** In: Gressner A, Arndt T (Hrsg.) Lexikon der Medizinischen Laboratoriumsdiagnostik. 2. Auflage. Springer Medizin Verlag, Heidelberg (2012).
7. Lakos G, Favaloro EJ, Harris EN, Meroni PL, Tincani A, Wong RC, Pierangeli SS. **International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies.** Arthritis Rheum 64 (2012) 1-10.
8. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. **International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).** J Thromb Haemost 4 (2006) 295-306.
9. Sangle NA, Smock KJ. **Antiphospholipid antibody syndrome.** Arch Pathol Lab Med 135 (2011) 1092-1096.
10. Wong RC, Favaloro EJ. **Clinical features, diagnosis, and management of the antiphospholipid syndrome.** Semin Thromb Hemost 34 (2008) 295-304.

MANUFACTURER AND BRAND DETAILS



Date Adopted	2023-07
Brand Name	AccuDiag™
REF 1495-55	AccuDiag™ - Anti-β2-Glycoprotein 1 IgG ELISA
Revision Date: 03-18-14	